The link I sent sends you to the twitch front page. You can go to videos to see the replay or this link below should send you there. https://www.twitch.tv/chimeraresearch/videos
With the entrance of RET inhibitor TPX-0046 into P1/2 last November, fast moving Turning Point Therapeutics now has a full slate of 3 clinical candidates. Soon, another ALK inhibitor is.
Apellis Pharmaceuticals is developing treatments through targeting the human complement cascade. Its most advanced product is C3 inhibitor APL-2. Pivotal trials are ongoing in PNH and geographic atrophy in age-related.
Constellation Pharmaceuticals presented some compelling data at ASH. In early results from 15 JAKi naive Myelofibrosis patients treated with a combination of BET inhibitor CPI-0610 and ruxolitinib, 12 (80%) achieved.
Constellation Pharmaceuticals is focused on the development of cancer therapeutics by targeting the epigenetic pathway. It has EZH2 and BET inhibitors in mid-stage clinical studies. Excitement in the stock is.
San Diego based Turning Point Therapeutics is an oncology focused biotech that completed a successful IPO in April this year, raising about $190M with pricing at $18/sh. As the stock.
I have been following Arqule off and on for quite some time. The company has been reborn after so many lost years pursuing its failed MET inhibitor ARQ 197. Hopes.
Aug 27, 2019 by Jason Chew Zogenix announced yesterday that it is acquiring privately held Modis Therapeutics. It gains access to the late stage substrate enhancement therapy, MT1621, for the.
Aug 23, by Jason Chew Arvinas is one of the newer names I’ve been covering. The company is developing a new class of drugs with a new modality known as.
Aug 19, 2019 by Jason Chew Zogenix ran into some unwelcome surprise this April when FDA kicked back its ZX008 (Fintepla) NDA with a Refuse to File letter. The two deficiencies cited.
Aug 14, 2019 by Jason Chew Zymeworks is perhaps one of my favorite stocks. The small/mid cap Canadian biotech has expertise in bispecific antibody technology. Bispecifics are an exploding field,.
Another week with another set of macro concerns. I was waiting to see if there would be any interesting biotech news but I guess not. There was some late last.
Pfizer (PFE) presented its first set of data (n=6) from the mini-dystrophin gene therapy for DMD (PF-06939926) at the PPMD conference on June 28th. Much speculations surrounded Pfizer’s decision to.
So that was unexpected. First, the market is down and sector is higher. Second, we got another large merger to digest. Obviously I will focus on the deal and its.
Sarepta Therapeutics (SRPT) has a long history with several inflection points through the years. Moving upward from a penny stock back in the days they used to be called AVI.
• Regenerative medicine company with late-stage studies in 3 indications • Ready to use GMP-certified manufacturing facility for PLX cells • Aging is often associated with debilitating medical conditions, massive.
BriaCell presented some data from the ongoing Phase IIa combination clinical trial of Bria-IMT™ with Merck’s (NYSE: MRK) KEYTRUDA® [(pembrolizumab)], as listed in ClinicalTrials.gov as NCT03328026, in advanced breast cancer.